Plus Therapeutics rises as FDA grants orphan drug tag for pediatric brain cancer treatment

Cerenome

08/04/2026 12:42

** Shares of biotech firm Plus Therapeutics PSTV.O rise 15% to $3.36 premarket

** Co says the FDA granted orphan drug designation to experimental drug reyobiq for pediatric malignant gliomas, a rare and aggressive childhood brain cancer, which is hard to treat with surgery or chemotherapy alone

** Co says reyobiq delivers targeted radiation directly into tumors to limit damage to healthy brain tissue

** The FDA has cleared the drug for testing in children; studies are also ongoing in other brain cancers and cancer spread to brain fluid - PSTV

** FDA grants orphan drug status to promote drug development for rare diseases affecting fewer than 200,000 people in the U.S.

** As of last close, stock down ~77% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))